Home » Topics » BioWorld Science

BioWorld Science
RSS

Bi-allelic loss of human APC2 is associated with recessive form of lissencephaly

Oct. 17, 2019

Preclinical evaluation of novel nonimmunogenic utrophin gene therapy for DMD

Oct. 17, 2019

Positive biomarker results presented from phase I study of XCUR-17

Oct. 17, 2019

Further clinical data presented from phase I/II bladder cancer study of Alpha1H

Oct. 17, 2019

First patient enrolled in phase II study of novel cystic fibrosis treatment, BI-1265162

Oct. 17, 2019

Hepagene begins phase I trial of FXR agonist HPG-1860 for NASH

Oct. 17, 2019

Enterprise Therapeutics receives funding for development of novel CF therapy

Oct. 17, 2019

Milasen, individualized gene therapy for rare genetic disease

Oct. 17, 2019

P63 is behind thalidomide birth defects

Oct. 17, 2019

Anticoagulants prevent AD symptoms

Oct. 17, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...